Search - tctmd.com

Displaying 121 - 140 of 149

Sort: Relevancy | Date

News Daily News

Less Aggressive HbA1c Targets Recommended by American College of Physicians

Michael O'Riordan

March 06, 2018

News Daily News

‘Call to Action’ in India, Where Hypertension and Diabetes Loom Large

Michael O'Riordan

January 30, 2018

News Daily News

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Michael O'Riordan

January 18, 2018

News Daily News

Gestational Diabetes Increases Risk of Ischemic Heart Disease

Michael O'Riordan

January 16, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Daily News

Air Pollution Tightly Tied to CV Disease, Chinese Study Confirms

Ashley Lyles

August 15, 2017

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

News Daily News

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Michael O'Riordan

July 06, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News Daily News

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Michael O'Riordan

June 08, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

Yael L. Maxwell

February 14, 2017

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

Advertisement

Less Aggressive HbA1c Targets Recommended by American College of Physicians

‘Call to Action’ in India, Where Hypertension and Diabetes Loom Large

Bariatric Surgery: Cardiometabolic Benefits Down, but Not Out, at 5 Years

Gestational Diabetes Increases Risk of Ischemic Heart Disease

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Air Pollution Tightly Tied to CV Disease, Chinese Study Confirms

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Higher BMI Linked to Increased Risk of CHD, Hypertension, and Diabetes

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content